Literature DB >> 9973523

Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells.

E S Sobel1, C Mohan, L Morel, J Schiffenbauer, E K Wakeland.   

Abstract

Sle1 is a potent autoimmune susceptibility locus on chromosome 1 originally identified in a genome scan of testcross progeny between the systemic lupus erythematosus-prone NZM2410 strain and C57BL/6. We subsequently produced B6.NZMc1, a congenic strain carrying the NZM2410-derived Sle1 genomic interval on the B6 background and demonstrated that Sle1 mediated the loss of tolerance to chromatin in both the B and T cell compartments. In this communication, we show by adoptive transfer experiments that the autoimmune phenotypes of Sle1 are completely reconstituted in B6 radiation chimeras receiving B6.NZMc1 bone marrow but not by the reciprocal reconstitution, demonstrating that Sle1 is functionally expressed in B cells. In additional experiments, cotransfer of mixtures of bone marrow derived from B6.NZMc1 and nonautoimmune congenic B6 mice carrying allelic T and B cell markers showed that only B cells derived from B6.NZMc1 bone marrow produced anti-chromatin autoantibodies. In contrast, increased expression of CD69 was equivalent in CD4+ T cells derived from either B6.NZMc1 or congenic B6 bone marrow, suggesting that either T cell population could be activated subsequent to loss of tolerance in the B cell compartment. These findings indicate that the expression of Sle1 in B cells is essential for the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973523

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Genetics and systemic lupus erythematosus.

Authors:  B P Tsao; J M Grossman
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

3.  Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; Shunhua Guo; Laurence Morel
Journal:  Arthritis Rheum       Date:  2010-08

Review 4.  Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.

Authors:  Aurélie De Groof; Patrice Hémon; Olivier Mignen; Jacques-Olivier Pers; Edward K Wakeland; Yves Renaudineau; Bernard R Lauwerys
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

5.  Altered IgG autoantibody levels and CD4(+) T cell subsets in lupus-prone Nba2 mice lacking the nuclear progesterone receptor.

Authors:  Alan H Wong; Nalini Agrawal; Grant C Hughes
Journal:  Autoimmunity       Date:  2015-04-10       Impact factor: 2.815

6.  Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.

Authors:  Anna L Peters; Laura L Stunz; David K Meyerholz; Chandra Mohan; Gail A Bishop
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

7.  Estrogen receptor alpha signaling promotes Sle1-induced loss of tolerance and immune cell activation and is responsible for sex bias in B6.Sle1 congenic mice.

Authors:  Shayla D Yoachim; Jenny S Nuxoll; Kimberly K Bynoté; Karen A Gould
Journal:  Clin Immunol       Date:  2015-04-07       Impact factor: 3.969

8.  Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis.

Authors:  Chuancang Jiang; Ming Lang Zhao; Marilyn Diaz
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

Review 9.  B cell depletion therapy in systemic lupus erythematosus.

Authors:  Jennifer Anolik; Iñaki Sanz; R John Looney
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

10.  Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites.

Authors:  Robin A Herlands; Jacqueline William; Uri Hershberg; Mark J Shlomchik
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.